Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature
- PMID: 20884114
- DOI: 10.1016/j.eururo.2010.08.041
Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature
Abstract
Context: The number and location of biopsy cores and the interpretation of prostate biopsy in different clinical settings remain the subjects of continuing debate.
Objective: Our aim was to review the current evidence regarding the performance and interpretation of initial, repeat, and saturation prostatic biopsy.
Evidence acquisition: A comprehensive Medline search was performed using the Medical Subject Heading search terms prostate biopsy, prostate cancer, detection, transrectal ultrasound (TRUS), nomogram, and diagnosis. Results were restricted to the English language, with preference given to those published within the last 3 yr.
Evidence synthesis: At initial biopsy, a minimum of 10 but not >18 systematic cores are recommended, with 14-18 cores in glands ≥ 50 cm³. Biopsies should be directed laterally, and transition zone (TZ) cores are not recommended in the initial biopsy setting. Further biopsy sets, either as an extended repeat or as a saturation biopsy (≥ 20 cores) including the TZ, are warranted in young and fit men with a persistent suspicion of prostate cancer. An immediate repeat biopsy is not indicated for prior high-grade prostatic intraepithelial neoplasia diagnosis given an adequate extended initial biopsy. Conversely, biopsies with atypical glands that are suspicious but not diagnostic of cancer should be repeated within 3-6 mo. Overall recommendations for further biopsy sets (a third set or more) cannot be made. Transrectal ultrasound-guided systematic biopsies represent the standard-of-care method of prostate sampling. However, transperineal biopsies are an up-to-standard alternative.
Conclusions: The optimal prostatic biopsy regimen should be based on the individualized clinical setting of the patient and should follow the minimum standard requirements reported in this paper.
Copyright © 2010 European Association of Urology. All rights reserved.
Similar articles
-
Prostate biopsy: who, how and when. An update.Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Can J Urol. 2005. PMID: 15780165 Review.
-
[Clinical problems of systematic prostate needle biopsy in the detection of prostate cancer].Gan To Kagaku Ryoho. 2003 Jan;30(1):16-20. Gan To Kagaku Ryoho. 2003. PMID: 12557699 Japanese.
-
Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.Eur Urol. 2010 Jan;57(1):1-8. doi: 10.1016/j.eururo.2009.08.011. Epub 2009 Aug 19. Eur Urol. 2010. PMID: 19720449
-
Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.Urology. 2009 May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4. Urology. 2009. PMID: 19195695
-
Improving cancer detection by prostate biopsy: the role of core number and site.Nat Clin Pract Urol. 2006 Oct;3(10):526-7. doi: 10.1038/ncpuro0602. Nat Clin Pract Urol. 2006. PMID: 17031375 Review. No abstract available.
Cited by
-
Computer-aided transrectal ultrasound: does prostate HistoScanning™ improve detection performance of prostate cancer in repeat biopsies?BMC Urol. 2015 Jul 30;15:76. doi: 10.1186/s12894-015-0072-z. BMC Urol. 2015. PMID: 26223353 Free PMC article.
-
Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611. Epub 2015 Aug 17. Cancer. 2015. PMID: 26280815 Free PMC article.
-
Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.World J Urol. 2014 Apr;32(2):461-7. doi: 10.1007/s00345-013-1130-3. Epub 2013 Jul 20. World J Urol. 2014. PMID: 23873356
-
Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.Int Braz J Urol. 2016 May-Jun;42(3):449-55. doi: 10.1590/S1677-5538.IBJU.2015.0155. Int Braz J Urol. 2016. PMID: 27286106 Free PMC article.
-
Using deep learning to detect patients at risk for prostate cancer despite benign biopsies.iScience. 2022 Jun 23;25(7):104663. doi: 10.1016/j.isci.2022.104663. eCollection 2022 Jul 15. iScience. 2022. PMID: 35832894 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical